<SUBMISSION>
<ACCESSION-NUMBER>0001181431-10-036651
<TYPE>4
<PUBLIC-DOCUMENT-COUNT>1
<PERIOD>20100701
<FILING-DATE>20100706
<DATE-OF-FILING-DATE-CHANGE>20100706
<REPORTING-OWNER>
<OWNER-DATA>
<CONFORMED-NAME>HARKNESS TIMOTHY
<CIK>0001231183
</OWNER-DATA>
<FILING-VALUES>
<FORM-TYPE>4
<ACT>34
<FILE-NUMBER>000-27188
<FILM-NUMBER>10940884
</FILING-VALUES>
<MAIL-ADDRESS>
<STREET1>MOLECULAR DEVICES CORP
<STREET2>1311 ORLEANS DRIVE
<CITY>SUNNYVALE
<STATE>CA
<ZIP>94089
</MAIL-ADDRESS>
</REPORTING-OWNER>
<ISSUER>
<COMPANY-DATA>
<CONFORMED-NAME>ACCELRYS, INC.
<CIK>0001002388
<ASSIGNED-SIC>7372
<IRS-NUMBER>330557266
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>0331
</COMPANY-DATA>
<BUSINESS-ADDRESS>
<STREET1>10188 TELESIS COURT, SUITE 100
<CITY>SAN DIEGO
<STATE>CA
<ZIP>92121-3752
<PHONE>(858) 799-5000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>10188 TELESIS COURT, SUITE 100
<CITY>SAN DIEGO
<STATE>CA
<ZIP>92121-3752
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>PHARMACOPEIA INC
<DATE-CHANGED>19951018
</FORMER-COMPANY>
</ISSUER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>rrd280925.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2010-07-01</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001002388</issuerCik>
        <issuerName>ACCELRYS, INC.</issuerName>
        <issuerTradingSymbol>ACCL</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001231183</rptOwnerCik>
            <rptOwnerName>HARKNESS TIMOTHY</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ACCELRYS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>10188 TELESIS COURT, SUITE 100</rptOwnerStreet2>
            <rptOwnerCity>SAN DIEGO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92121</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2010-07-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>13208</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>13208</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Received in exchange for 16,929 shares of Symyx Technologies, Inc. (&quot;Symyx&quot;) common stock in connection with the merger of Alto Merger Sub, Inc., a wholly-owned subsidiary of Accelrys, Inc. (&quot;Accelrys&quot;), with and into Symyx, with Symyx surviving as a wholly-owned subsidiary of Accelrys (the &quot;Merger&quot;).  On the effective date of the Merger, the closing price of Symyx's common stock was $5.01 per share and the closing price of Accelrys's common stock was $6.66 per share.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Shannon Catalano, Attorney-In-Fact</signatureName>
        <signatureDate>2010-07-06</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
